Clinical Updates in Chronic Myeloid Leukemia: New Understandings in Disease Diagnosis, Monitoring and Personalized Therapeutic Regimens Utilizing Tyrosine Kinase Inhibitors

Advance your understanding on how to better diagnose, treat, and monitor CML. Expert faculty from MD Anderson recently gave a series of lectures across the country on the latest research and treatment regimen recommendations in CML. Highlighting key takeaways from this meeting series, faculty review the role of ABL tyrosine kinase inhibitor (TKI) agents in advancing treatment and delivering up-to-date care as well as discuss safety and tolerability of various approved TKIs in CML. They examine practical clinical strategies for managing potential toxicities resulting from treatment as well as optimizing health outcomes by personalizing treatment regimens based on patient-centered needs and disease characteristics.

This expert roundtable includes downloadable resources to improve care for your CML patients featuring key summary points and includes slides from the national visiting lecture series.

GOALS

-Acquired knowledge on evaluating patients’ health status and recognizing therapeutic options in regards to patient profiles. (Knowledge, Competence)
-Enhanced knowledge of efficacy and tolerability, patient monitoring management, tied to available therapeutic regimes along with increased awareness of guideline recommendations. (Knowledge, Competence)
-Clinicians will be informed of the different TKIs available for frontline treatment along with their unique toxicity profiles/drug-drug interactions leading to better patient monitoring and controlling adverse effects. (Knowledge, Competence, Performance)